KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Intangibles (2016 - 2025)

Sarepta Therapeutics has reported Intangibles over the past 15 years, most recently at $19.0 million for Q4 2025.

  • Quarterly results put Intangibles at $19.0 million for Q4 2025, down 29.33% from a year ago — trailing twelve months through Dec 2025 was $19.0 million (down 29.33% YoY), and the annual figure for FY2025 was $19.0 million, down 29.33%.
  • Intangibles for Q4 2025 was $19.0 million at Sarepta Therapeutics, down from $29.7 million in the prior quarter.
  • Over the last five years, Intangibles for SRPT hit a ceiling of $30.5 million in Q2 2025 and a floor of $7.2 million in Q1 2023.
  • Median Intangibles over the past 5 years was $16.1 million (2021), compared with a mean of $18.8 million.
  • Biggest five-year swings in Intangibles: tumbled 46.78% in 2022 and later surged 301.86% in 2024.
  • Sarepta Therapeutics' Intangibles stood at $14.2 million in 2021, then tumbled by 46.78% to $7.6 million in 2022, then soared by 31.96% to $10.0 million in 2023, then skyrocketed by 168.87% to $26.9 million in 2024, then decreased by 29.33% to $19.0 million in 2025.
  • The last three reported values for Intangibles were $19.0 million (Q4 2025), $29.7 million (Q3 2025), and $30.5 million (Q2 2025) per Business Quant data.